Introduction
Technological advances have recently supported procedural changes and improvements in aortic valve replacement by favoring the development of novel surgical approaches and new valve prostheses. Amongst them, sutureless (Perceval; Livanova, London, UK) and rapid-deployment valves (Intuity Valve System; Edwards Lifesciences, Irvine, CA, USA) are successfully used in several settings of conventional and minimally invasive procedures (SUAVR, sutureless aortic valve replacement). They are currently one of the more appealing substitutes for surgeons, who can take advantage of their simplified implantation technique whilst maintaining auxiliary cardiopulmonary bypass and cardioplegic arrest (1, 2) . On the other hand, transcatheter aortic valves (TAVI) are delivered in a microinvasive fashion (µ-ICS, in a beating and non-assisted heart) (3) and are considered a treatment option primarily for high-risk patients (4, 5) . Current guidelines (6, 7) and data available from ongoing randomized trials (8) confirm TAVI's potential benefits in some elective patients with intermediate risk. In this paper, we aim to share our perspective on therapeutic approaches for patients with severe aortic stenosis by reviewing hemodynamic data and clinical evidences upon SUAVR versus TAVI.
State of art
In 2016, our group published the results of a multicenter study on clinical and hemodynamic comparisons between SUAVR and TAVI (9 One study directly compared hemodynamic performance of Sapien versus Perceval valves and focused specifically on patients presenting with small aortic annulus (≤21 mm). The authors confirmed higher gradients in the SUAVR group, although finding similar postoperative indexed effective orifice area between SUAVR and TAVI (14) . It has been shown that the incidence of severe PPM after Perceval implantation ranges approximately from 0 to 11% (15), after Intuity from 6% to 15% (16, 17) and is about 8% after TAVI (up to 27% if moderate degree of PPM is considered) (18) . There are no data about the impact of PPM after SUAVR on survival, but it has been shown that PPM after TAVI does not have an impact on late-term survival (18) . The major difficulty in interpreting these data arises from the variability of TAVI devices included in these papers, on their retrospective and propensity-matched nature and on the fact that the only SUAVR prostheses considered is the Perceval Valve (and the withdrawn 3F), but no data are available on the comparison between TAVI and the other commercially-available sutureless prosthesis, the Intuity Valve.
In summary, the available data demonstrate that SUAVR prostheses perform better than TAVI in terms of paravalvular leak. However SUAVR valves seem to have higher postoperative transvalvular gradients, but the real clinical impact of this finding is still to be determined.
Discussion
Patients with high surgical risk, advanced age or those judged inoperable are typically good candidates for the TAVI procedure, whereas the appropriateness of this approach in younger patients with a lower risk profile is still under debate (18) . In fact, recently published European guidelines (7) recommend TAVI in intermediate risk patients (class Ib, LOE B), but an age <75 years still favors conventional surgery and suggests that the choice of the intervention must take into account the characteristics of the patients as well as advantages and disadvantages of every valve substitute. Therefore, the crucial aspects in considering the choice of best therapeutic approach and most suitable aortic substitute, especially in patients with intermediate-to low-risk, are: (I) evaluation of the hemodynamic performance (PVL and transvalvular gradients); (II) valve durability; (III) rate of pacemaker implantation; (IV) patients' quality of life and (V) costeffectiveness analysis.
Hemodynamic performance
Paravalvular leak after TAVI is mostly due to inappropriate annular sizing, suboptimal positioning and irregular calcium distribution over the valve annulus and leaflets which determines an inhomogeneous valve expansion. PVL has shown to be correlated to increased mortality rate at 1 year (19, 20) , especially in patients with preoperative valve stenosis and no regurgitation (with no previous ventricular dilation) (21) . For this reason, when it comes to treating intermediate and low risk patients, the occurrence of "more than mild" PVL should unquestionably be avoided. Transcatheter devices specifically designed to solve PVL after TAVI are not currently available and results after closure with other kind of vascular occluders are suboptimal (22) . New generation TAVI devices have already been engineered with specific novel features capable of reducing, but still not eliminating, PVL. Conversely, SUAVR requires annular decalcification as in conventional surgery, thus explaining the reduced incidence of PVL observed in comparative studies. PVL after SUAVR is related to wrong valve sizing and is more frequent during the learning phase. As shown, current evidence supports that SUAVR provides significant lower incidence of PVL and therefore it should be, so far, considered superior to TAVI on this matter. However, whilst currently available data demonstrate that SUAVR provides statistically significant higher gradients than TAVI, there is no evidence of a significant clinical impact. In fact, the incidence of PPM is similar after TAVI and SUAVR, in studies focusing only on patients with a small aortic annulus. Furthermore, PPM in TAVI seems not significantly associated to late mortality (23) . Possible explanations for lower transaortic gradients in TAVR, compared to SUAVR, are: (I) the surgical technique that clearly differs between TAVI and SU-AVR and its postoperative implications; in particular, anemia, hemodilution, and inflammation may have a role in the increased gradients found at discharge in the SU-AVR group, and (II) TAVR are designed with a circumferential anchoring stent that protrudes into the LVOT, which is also expanded during valve implantation and may explain the lower gradients. On the contrary, Perceval prostheses do not reach the subannular region. While TAVI is considered superior to conventional valve prostheses in terms of PPM (23), there are no data supporting the superiority compared to SUAVR.
Valve durability
The intermediate risk patient profile often entails a younger patient age and longer life expectancy, which therefore makes prosthesis durability a major concern. Durability in TAVI is related to the biological nature of the valve leaflets and to pre-procedural steps, such as valve crimping and intravalvular balloon inflation, which is essential for a transcatheter delivery. Several reports have been recently published showing specific lesions (transverse fractures and longitudinal cleavages) on pericardial leaflets, especially in balloon-expandable valves (24) (25) (26) (27) , phenomena that can potentially lead to valve deterioration. Unfortunately, longterm durability data after TAVI are still not available in the literature and just a few reports present results in patients with 5-year follow-up (28) that, for valve prosthesis, are not considered sufficient. For instance, the Toronto stentless porcine valve was withdrawn from the market because it showed initial valve deterioration signs only 7 years after implantation (29) . Therefore, for both TAVI and SUAVR, longer follow-up is needed to reach timepoints when valverelated adverse events are more likely to occur.
Rate of pacemaker implantation
No significant differences are found in the literature in terms of incidence of AV block and pacemaker implantation between SUAVR and TAVI (8, 30, 31) . Although currently available SUAVR devices show similar rates of PM implantation, this is not the case in TAVI devices. There is wide variability in terms of postoperative need for PM implantation among the different TAVI devices, as some prostheses show an incidence of PM implantation as high as 28% with a rate of new or worsened left bundle branch block of 78% (32) . Pacemaker implantation is associated with several complications (endocarditis, device replacement, ventricular dyssynchrony, etc.) and it has also been related to higher 1-year mortality (33) after TAVI.
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Quality of life and cost effectiveness analysis
Finally, quality of life and cost effectiveness analysis must be considered during screening and operative decision processes in patients with AS and intermediate surgical risk. In actuality, patients seem to similarly perceive their quality of life after conventional surgery, SUAVR (especially if performed in minimally invasive fashion) (34) and TAVI at 1-and 2-year follow-up. Nevertheless, procedural costs become comparable to conventional surgery (standard of care) only if hospital length of stay after TAVI lasts 5-6 days less than SAVR (35, 36) . Table 1 summarizes advantages and disadvantages of all surgical options for patients suffering from severe aortic valve stenosis.
Comments and perspective
The best strategy to minimize procedural complications, optimize valve hemodynamics and improve patients' clinical outcomes relies on the establishment of a meticulous preoperative planning process. In particular, preoperative high resolution CT scanning enables detailed aortic root and valve analysis (included calcium quantification and mapping) with 3D model reconstruction of the aortic root. Sutureless and transcatheter valves should not be considered as competitors, they have their own field of application and both are valid and surgical options. In fact, in specialized centers, where case-specific preoperative planning is done and availability of all prostheses is ensured to qualified surgeons, the choice of the most appropriate device is totally unbiased. For instance, in patients with asymmetrical distribution of calcium and/or massive and bulky annular calcification-both morphological predictors of PVL and BAV after TAVI-SUAVR may be a better option. Finally, SUAVR significantly facilitates a minimally invasive surgical approach and it may be always performed in patients with isolated AS and low surgical risk, or in the case where any other associated cardiac surgery is indicated.
Conclusions
SUAVR and TAVI are both valid surgical alternatives to conventional valve replacement in patients with AS. Lower transvalvular gradients, but higher PVL, are commonly found after TAVI. Accurate preoperative screening and prosthesis selection are mandatory to properly select casespecific best treatment options, based on anatomical and surgical characteristics. 
